Key result
Intracoronary urokinase and intravenous abciximab successfully resolved chest pain and eliminated the coronary thrombus in a patient with acute myocardial infarction and a myocardial bridge.
Case Report (n=1)
No
Intracoronary urokinase and intravenous abciximab successfully treated an acute myocardial infarction caused by a coronary thrombus associated with a myocardial bridge and slow coronary flow.
May support feasibility of urokinase plus abciximab in bridge-related thrombus; hypothesis-generating case report requiring prospective validation.
Acute myocardial infarction is generally caused by the rupture or erosion of an atheromatous plaque and thrombosis. Acute myocardial infarction associated with a myocardial bridge or slow coronary flow is rare. We experienced a case of acute myocardial infarction, caused by a coronary thrombus in association with a myocardial bridge and slow coronary flow. A 33-year-old man presented with the sudden onset of chest pain. A diagnostic coronary angiography revealed an intraluminal contrast-filling defect, proximal to the myocardial bridge in the left anterior descending artery, with TIMI-2 flow. After an intracoronary injection of 150,000 units of urokinase and an intravenous injection of abciximab, the patient’s chest pain subsided, with the follow-up coronary angiography showing the disappearance of the coronary thrombus. (Korean Circulation J 2005;35:639-642)
No takes yet. Share an insight, caveat, or question.
Uhm et al. (2005) conducted a case report in Acute myocardial infarction (n=1). Urokinase and abciximab was evaluated on Chest pain resolution and thrombus disappearance. Intracoronary urokinase and intravenous abciximab successfully resolved chest pain and eliminated the coronary thrombus in a patient with acute myocardial infarction and a myocardial bridge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: